Compare CLDT & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLDT | ALT |
|---|---|---|
| Founded | 2009 | 1997 |
| Country | United States | United States |
| Employees | 16 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 502.8M | 421.5M |
| IPO Year | N/A | 2005 |
| Metric | CLDT | ALT |
|---|---|---|
| Price | $11.56 | $2.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $11.00 | ★ $17.67 |
| AVG Volume (30 Days) | 421.9K | ★ 2.6M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.13% | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | $2.94 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $610.21 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $6.08 | $2.56 |
| 52 Week High | $11.62 | $7.73 |
| Indicator | CLDT | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 78.92 | 36.69 |
| Support Level | $6.26 | $2.56 |
| Resistance Level | N/A | $4.19 |
| Average True Range (ATR) | 0.26 | 0.12 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 96.15 | 0.00 |
Chatham Lodging Trust is a U.S.-based real estate investment trust that invests in upscale extended-stay hotels. The firm operates across various states in the U.S., including California, New York, Texas, Florida, Minnesota, Massachusetts, and Pennsylvania, among others. Substantially all of the company's assets are held and operated by its operating partnership, Chatham Lodging, LP. Chatham Lodging LP and its subsidiaries lease the overall company's hotels. Chatham's revenue streams include room, food and beverage, and other. The room comprises the majority of its total revenue. Chatham's hotels operate under various brands, which include Hilton, Marriott, and Hyatt.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.